I understand there's lots of shareholders out there that got burned, I've followed this company for 15 years or so myself, but never really saw much value until last year when the stock was in the pennies after the reverse split, during tax-loss selling season, and as the company reported their first system sales in years.
A closer look revealed that PET MPI was being proven superior to SPECT in several clinical studies and the previous scarcity of Rb-82 radiopharmacueticals had been addressed with the entry of a new Rb-82 generator to the market: https://www.jstage.jst.go.jp/article/anc/3/1/3_17-00047/_pdf
This January 2019 SNMMI newsletter shows the traction they are gaining:
"Studies have shown that PET-MPI provides higher diagnostic accuracy than SPECT-MPI for detection of coronary artery disease, having a higher sensitivity and specificity as well as lower radiation dose during a shorter examination time period3. Despite this, some insurance companies will not cover the cost of the MPI study without an equivocal positive or negative finding from other diagnostic methods.
I appreciate that the company is more focused on building their business than issuing PR at this point, this is the type of situation I like to invest in, as a patient, long-term investor.